The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Warning Letter to EvexiPEL's Pellet Supplier, Farmakeio BHRT Options The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and BPC 157 Banned: Key Facts on the Latest FDA Decision Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed BPC 157: Miracle Healing Peptide or Hidden Danger?